Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Appili Therapeutics Inc.
  6. News
  7. Summary
    APLI   CA03783R1073

APPILI THERAPEUTICS INC.

(APLI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Appili Details "Positive" One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate, Change to Board of Directors

11/19/2021 | 08:20am EST


© MT Newswires 2021
All news about APPILI THERAPEUTICS INC.
2021Appili Therapeutics - Press Release Correction
AQ
2021Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners
AQ
2021Appili Therapeutics Loses 4% as Revises Funding Agreement with The Lind Partners
MT
2021Appili Therapeutics Revises Funding Agreement with The Lind Partners
MT
2021Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
AQ
2021Appili Details "Positive" One Year Challenge Results from Preclinical Study Evaluating ..
MT
2021Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
BU
2021Appili Therapeutics Inc. Announces Positive One Year Challenge Results from Preclinical..
CI
2021Appili Therapeutics Inc. Announces Resignation of Josef Vejvoda from the Board of Direc..
CI
2021Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan..
AQ
More news
Financials
Sales 2022 - - -
Net income 2022 -31,8 M -24,9 M -24,9 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 8,91 M 6,98 M 6,97 M
Capi. / Sales 2022 -
Capi. / Sales 2023 41,4x
Nbr of Employees 15
Free-Float -
Chart APPILI THERAPEUTICS INC.
Duration : Period :
Appili Therapeutics Inc. Technical Analysis Chart | APLI | CA03783R1073 | MarketScreener
Technical analysis trends APPILI THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,13 CAD
Average target price 0,25 CAD
Spread / Average Target 100%
EPS Revisions
Managers and Directors
Armand L. Balboni Chief Executive Officer & Director
Kenneth G. Howling Chief Financial Officer
Ian C. Mortimer Chairman
Yoav Golan Chief Medical Officer
Theresa Matkovits Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APPILI THERAPEUTICS INC.8.70%7
GILEAD SCIENCES, INC.-5.16%86 377
REGENERON PHARMACEUTICALS-1.05%65 339
VERTEX PHARMACEUTICALS10.66%61 849
WUXI APPTEC CO., LTD.-11.62%47 600
BIONTECH SE-37.08%39 180